← Guides

How should chain of identity and chain of custody be checked in cell and gene therapy batch records?

By Savi C., Co-Founder · Published Nov 16, 2026

Two related chains

Chain of identity links a patient or donor to their material and to the finished product at every step. For an autologous therapy, a break means a patient could receive someone else’s cells. Chain of custody records who held the material, where, when and under what conditions. The second term has no single regulatory definition we could find; it is common practice to track it alongside identity because the two fail together at handoffs.

The regulatory anchors differ by product and region. FDA’s CAR T guidance points to Part 1271 Subpart D, and 21 CFR 1271.290 requires a distinct identification code for HCT/Ps that does not use the patient’s name, social security number or medical record number, except as 1271.55(a)(1) allows. In the EU, Regulation (EC) No 1394/2007 Article 15 requires a traceability system for advanced therapy products and data kept for at least 30 years after product expiry. Some organizations use the ISBT 128 Chain of Identity Identifier published by ICCBBA in 2023; adoption varies, so use whatever identifier scheme your procedures define.

The guidance’s recommendations are written for CAR T cells, though FDA notes they may apply to other genetically modified lymphocyte products. Apply them to other cell and gene therapies through your own risk assessment.

Chain of identity and custody checks in the batch record

Receipt of starting material

  • Both unique identifiers on the collection label match the order or scheduling record and the batch record header
  • Collection site, collection date and time recorded and consistent across the shipping documents
  • Shipping container and temperature record attached and inside the validated conditions
  • Receipt recorded with time and the person receiving, closing the custody gap from courier to facility

During manufacture

  • A documented label check, with both identifiers, before each processing step, as the guidance recommends
  • Every container, bag and sample generated carries the identifiers, and labels issued, used and destroyed reconcile
  • Only one patient’s material open in a workspace at a time, if your procedures require segregation, with line clearance recorded
  • Cryostorage location, time in and time out recorded for each hold

Final product and release

  • Final label identifiers match the starting material and the batch record throughout
  • Autologous product labeled FOR AUTOLOGOUS USE ONLY, with the other statements 21 CFR 1271.90(c) requires where applicable
  • Any identifier mismatch, relabeling or unreadable label handled as a deviation and closed before release
  • Shipment to the treatment site recorded with conditions and handoff, so custody continues to the bedside check

Where identity breaks usually show up in review

Point in the record

Collection to receipt

What to compare

Collection label, chain of custody form and receiving entry

Point in the record

Each processing step

What to compare

Container label, step header and the recorded label check

Point in the record

Samples and testing

What to compare

Sample labels, laboratory records and certificate of analysis

Point in the record

Cryostorage and holds

What to compare

Storage location log and batch record entries

Point in the record

Final label and shipment

What to compare

Final label, release record and shipping documents

How Litewave fits

Identity checks are repetitive comparisons of the same identifiers across many pages and documents, which is exactly where manual review gets tired. Litewave reads paper or electronic records, checks every entry against your master record and specifications, and shows QA only the exceptions, each linked to the page it came from. Litewave proposes, qualified people approve. Our published results come from pharmaceutical manufacturing; we do not claim cell or gene therapy customers or results. For general record integrity, see What does ALCOA+ mean for batch records?

Questions we get asked

How many identifiers does FDA expect on an autologous CAR T product?

FDA’s January 2024 CAR T guidance recommends at least two unique identifiers, with label checks built into the batch record before each processing step and two independent patient and label checks at the bedside. It is a recommendation, not a regulation.

Can the patient’s name be used as the identifier?

Not as the distinct identification code under 21 CFR 1271.290, which must be created for tracking and may not include a name, social security number or medical record number except as 1271.55(a)(1) allows. Patient identifiers used at the clinical site are a separate matter governed by your procedures.

Does autologous material need a donor eligibility determination?

No. FDA’s guidance notes that autologous leukapheresis material does not require one under 21 CFR 1271.90(a)(1), but the product must then carry the labeling statements in 1271.90(c), which the batch record review should confirm.

Sources

  1. FDA CBER, Considerations for the Development of CAR T Cell Products (January 2024)
  2. 21 CFR 1271.90, Donor eligibility exceptions and labeling (eCFR)
  3. 21 CFR 1271.290, Tracking (eCFR)
  4. Regulation (EC) No 1394/2007 on advanced therapy medicinal products (EUR-Lex)
  5. ICCBBA, ISBT 128 Standard Chain of Identity (CoI) Identifier, ST-028